Health-related quality of life and blood pressure 12 months after renal denervation

Lambert, Gavin W.; Hering, Dagmara; Marušić, Petra; Thorp, Alicia A.; Sata, Yusuke; Lee, Rebecca; Duval, Jacqueline; Hammond, Louise; Head, Geoffrey A.; Esler, Murray; Lambert, Elisabeth; Dixon, John; Dhar, Arup; Barton, David; Schlaich, Markus P.

doi:10.1097/hjh.0000000000000698

Cited by 7 publications

(7 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Systolic BP was correlated with anxiety and depression, and there was a trend toward a correlation in heart rate and anxiety, and intensity of headache and diastolic BP . In a separate investigation, Lambert and colleagues reported a decrease in office systolic BP in patients with resistant hypertension, as well as trait anxiety, depression, and the Short Form‐36 mental component summary score after RDN. Lambert and associates also found, similar to our analysis, differences in post‐RDN quality‐of‐life measures based on sex.…”

Section: Discussionmentioning

confidence: 95%

“…24 Systolic BP was correlated with anxiety and depression, and there was a trend toward a correlation in heart rate and anxiety, and intensity of headache and diastolic BP. 24 In a separate investigation, Lambert and colleagues 22 38 Blinding will be maintained and EQ-5D-3L will also be recorded at baseline and up to 1 year. This will be the first trial to date to compare quality of life between blinded patients out to 1 year and should add further insight into the relationship between RDN therapy and improved quality of life.…”

Section: Discussionmentioning

confidence: 99%

“…However, limited information exists on the impact of RDN on quality of life, including anxiety and depression, as well as pain and discomfort, in a large population of real-world patients. [21][22][23][24] The Global SYMPLICITY Registry is the largest ongoing, prospective, open-label, multicenter, international registry conducted to evaluate the safety and effectiveness of RDN in real-world patients. The EuroQoL five-dimensions three-level questionnaire (EQ-5D-3L) is employed prospectively in the Global SYMPLICITY Registry.…”

Section: Introductionmentioning

confidence: 99%

“…Although one recent sham‐controlled study showed a neutral result, Azizi and colleagues reported that RDN in combination with standardized stepped‐care antihypertensive treatment decreases ambulatory BP more than the same standardized stepped‐care antihypertensive treatment alone. However, limited information exists on the impact of RDN on quality of life, including anxiety and depression, as well as pain and discomfort, in a large population of real‐world patients …”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Improvement in health‐related quality of life after renal sympathetic denervation in real‐world hypertensive patients: 12‐month outcomes in the Global SYMPLICITY Registry

Kindermann

Wedegärtner

Mahfoud

et al. 2017

J of Clinical Hypertension

View full text Add to dashboard Cite

Renal denervation has been shown to reduce blood pressure in patients with uncontrolled hypertension, but less is known about its impact on quality of life. This analysis evaluated 12‐month blood pressure and quality of life outcomes in 934 patients from the Global SYMPLICITY Registry who completed the EuroQoL five‐dimensions three‐level questionnaire (EQ‐5D‐3L). At baseline, 32% of patients reported anxiety/depression and 48% reported pain/discomfort. At 12 months (n=496), office and 24‐hour ambulatory systolic blood pressure were reduced by 13.9±26.6 and 7.7±19.3 mm Hg, respectively, and 8% (P<.001) more patients reported no problems in anxiety/depression. Furthermore, numerically more patients reported no problems in pain/discomfort (4%, P=.08). Perceived health‐related quality of life (visual analog scale) improved from baseline to 12 months (68±18 vs 73±17, P<.001), and the improvement was largest among patients with severe anxiety/depression at baseline (50±24 vs 64±22, P=.005 [n=32]). In this analysis, renal denervation was associated with a significant improvement in health‐related quality of life, particularly anxiety/depression.

show abstract

Section: Discussionmentioning

confidence: 95%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Improvement in health‐related quality of life after renal sympathetic denervation in real‐world hypertensive patients: 12‐month outcomes in the Global SYMPLICITY Registry

Kindermann

Wedegärtner

Mahfoud

et al. 2017

J of Clinical Hypertension

View full text Add to dashboard Cite

show abstract

“…However, there was no correlation between improvement of QoL and the magnitude of BP reduction [22]. A recently published study assessed the effect of RDN on BP and health-related QoL 12 months after RDN and revealed that RDN in patients with confirmed resistant hypertension is associated with a reduction in BP and a sustained improvement in mental health-related aspects of QoL [23]. Another study reported that sufficient BP reduction by RDN and time following therapeutic success lead to significant improvements in patient QoL and a loss of anxiety in 93% of recipients [24].…”

Section: Discussionmentioning

confidence: 99%

Long-term quality of life and clinical outcomes in patients with resistant hypertension treated with renal denervation

Krawczyk‐Ożóg

Tokarek

Moczała

et al. 2016

pwki

View full text Add to dashboard Cite

IntroductionPharmacological treatment combined with lifestyle modifications is an effective treatment for arterial hypertension. However, there are still patients who do not respond to standard treatments. Patients with pharmacologically resistant hypertension may benefit from renal denervation (RDN).AimTo assess long-term quality of life (QoL) after RDN and effectiveness in reduction of blood pressure (BP) in patients with resistant hypertension.Material and methodsFrom 2011 to 2014, 12 patients with previously diagnosed resistant hypertension, treated by RDN, were included in this study. The QoL was assessed using a standardized Polish version of the Nottingham Health Profile questionnaire (NHP).ResultsThe median age was 54 (IQR: 51–57.5) years. Mean baseline ambulatory pre-procedural systolic/diastolic BP was 188/115 ±29.7/18 mm Hg. The mean values of systolic/diastolic BP measured perioperatively and 3, 6, 12 and 24 months postoperatively were 138/86, 138/85, 146/82, 152/86, and 157/91. All p-values for mean systolic and diastolic BP before versus successive time points after RDN were statistically significant; p-value for all comparisons < 0.05. Improvement of QoL was only observed in two sections of the NHP questionnaire: emotional reaction and sleep disturbance. The analysis of the NHP index of Distress (NHP-D) showed a lower distress level perioperatively and 3, 6, 12 and 24 months after RDN as compared to baseline. The RDN was not associated with any significant adverse events.ConclusionsPatients with pharmacologically resistant hypertension treated with RDN achieved significant reduction in BP during 24-month follow-up. Furthermore, a significant improvement in the QoL was observed in those patients.

show abstract

Renal denervation in hypertension patients: Proceedings from an expert consensus roundtable cosponsored by SCAI and NKF

Kandzari

Townsend

Bakris

et al. 2021

Cathet Cardio Intervent

View full text Add to dashboard Cite

Despite the availability of efficacious pharmacological treatments, hypertension remains the leading global cause of death and disability, 1 and rates of blood pressure (BP) control are stagnant, if not modestly declining. In the United States alone, for example, more than one-half of individuals with hypertension do not meet societal or guideline-directed BP goals, representing more than 29 million people. 2,3 Although reasons are multifactorial, patient non-adherence, physician inertia, as well as barriers such as lack of social support, depression and complex polypharmacy regimens are major contributors to lack of BP goal achievement.Interventional strategies, such as catheter-based renal denervation (RDN) using radiofrequency energy, ultrasound, or perivascular injection of neurotoxic agents, are gaining increasing attention. The rationale for RDN is to interrupt the activity of afferent and efferent

show abstract

Health-related quality of life and blood pressure 12 months after renal denervation

Abstract: These results indicate that in patients with confirmed resistant hypertension, RDN is associated with a reduction in BP and a sustained improvement in mental health-related aspects of QoL.

Cited by 7 publications

References 60 publications

Improvement in health‐related quality of life after renal sympathetic denervation in real‐world hypertensive patients: 12‐month outcomes in the Global SYMPLICITY Registry

Improvement in health‐related quality of life after renal sympathetic denervation in real‐world hypertensive patients: 12‐month outcomes in the Global SYMPLICITY Registry

Long-term quality of life and clinical outcomes in patients with resistant hypertension treated with renal denervation

Renal denervation in hypertension patients: Proceedings from an expert consensus roundtable cosponsored by SCAI and NKF

Contact Info

Product

Resources

About